Inflammatory bowel disease is characterised by significant interindividual heterogeneity. With a wider selection of pharmacological and non-pharmacological interventions available and in advanced developmental stages, a priority for the coming decade is to determine accurate methods of predicting treatment response and disease course. Precision medicine strategies will allow tailoring of preventative and therapeutic decisions to individual patient needs. In this review, we consider the future of precision medicine in inflammatory bowel disease.